Previously he headed corporate and business development for multiple innovative life science companies including Allocure, Vitae Pharmaceuticals and Pharmacopeia. Kevin began his career at Harvard University’s Office of Technology Licensing. In addition to Chimeron, his current and past Board memberships include UAMS Bioventures, Hibercell, Ultivue, and Board observer of Iteos.

Show Less

Previously, at the Wistar Institute in Philadelphia, he worked on understanding RNA biochemistry, with emphasis on biogenesis and maturation of small RNAs.  His research is published in high-profile journals including Nature, Cell, EMBO.  Tim obtained his Ph.D. at the University of Georgia and has an MBA from Columbia Business School.

Show Less

Most recently, she spent 10 years at BioAgilytix Labs, building the finance function from the ground up and played a pivotal role in due diligence through two sales of the Company. Prior to BioAgilytix Labs, she was a Partner with Rankin McKenzie, a leading provider of fractional CFOs and Controllers in the Research Triangle Park, NC area for eight years. At Rankin McKenzie, she provided CFO services encompassing all aspects of finance processes as well as setting up human resource policies to a variety of mostly life science start-up companies.

Monica received her B.S. magna cum laude in Business Administration, Accounting Emphasis from Wingate University and is a licensed Certified Public Accountant in North Carolina.

Show Less

Before founding Colorado Health and Tech Centers (CHTC) and NOVEL351K, he founded BioAgilytix Labs, one of the most successful multi-billion dollar Contract Research Organizational known internationally. Before these, he worked for various organizations, including AAIPharma, Bayer Biologicals, Talecris BioTherapeutics (Grifols), Nobex Corporation, GlaxoSmithKline, and IGEN International. Dr. Safavi obtained his B.S. in Biochemistry from UCLA, his Ph.D. in Biochemistry from the University of Kentucky Medical School, and completed a two-year postdoctoral assignment at the Emory University, Department of Pathology.

Show Less

Prior to founding Dreavent, he led several major transformations in high-tech multinational companies holding top management positions, including Rolls Royce, where he was awarded for excellent results achieved with the transformation he led of the engine externals subsidiary, ITP Externals. He is considered a dynamic executive leader with industrial and high technology business experience in leading new ventures, M&A, private equity, and holds an MSc in Organizations Engineering from the University of Navarra and Coaching from M&A Associates.

Show Less

Tony is currently CEO of Evox Therapeutics, which is developing exosome therapeutics as another new transformative drug modality. Prior to Evox, Tony was CSO of Ablynx, where he led all of the company’s non-clinical R&D operations and played a key role in the approval of the 1^st single domain antibody drug, caplacizumab. Prior to Ablynx, Tony was the founding CSO at Moderna Therapeutics and pioneered modified mRNA as a new therapeutic modality for both rare diseases and as vaccines, CSO of antibody-based immuno-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality, including overseeing the development of the now 1^st approved RNAi delivery system and the development of several RNAi drugs including inclisiran. Also, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also serves on the Scientific Advisory Boards of MiNA Therapeutics, LIfT BioSciences, and Healion Biosciences. Tony earned his Ph.D. in Immunology from Harvard University.

Show Less